The use of antipsychotic medications, or neuroleptics, has been a mainstay in the treatment of severe psychiatric disorders for decades. However, a significant and often debilitating side effect of this treatment is the development of Neuroleptic-induced dyskinesia , a movement disorder characterized by involuntary, repetitive movements. This condition is a major concern in psychiatric practice, affecting a substantial proportion of patients on long-term antipsychotic therapy. The global market for tardive dyskinesia, which is the most common form of neuroleptic-induced dyskinesia, was valued at USD 1.68 billion in 2025 and is projected to grow to USD 2.43 billion by 2035.

Neuroleptic-induced dyskinesia is primarily associated with the use of first-generation ("typical") antipsychotics, although it can also occur with second-generation ("atypical") antipsychotics, albeit at lower rates. The risk increases with the duration of treatment and the cumulative dose of the medication. The condition is believed to result from an imbalance in the brain's dopamine system, which is altered by long-term exposure to dopamine receptor-blocking drugs. The movements typically involve the orofacial region, including the tongue, lips, and jaw, but can also affect the limbs and trunk. The emergence of this side effect can be distressing for patients and may lead to non-adherence to the essential psychiatric medication.

The Clinical Burden and Diagnosis

The clinical burden of neuroleptic-induced dyskinesia is significant. The involuntary movements can be socially embarrassing and interfere with daily activities, such as eating, speaking, and walking. The condition can also contribute to stigma and reduce quality of life. Diagnosis is based on clinical observation, often using standardized rating scales like the Abnormal Involuntary Movement Scale (AIMS). It is crucial for clinicians to regularly screen patients on long-term antipsychotic therapy for the development of dyskinesia to facilitate early intervention. The management of this condition can be challenging, involving strategies such as reducing the antipsychotic dose, switching to a different medication, or adding specific treatments for the dyskinesia.

Treatment Strategies and Future Outlook

The treatment landscape for neuroleptic-induced dyskinesia has evolved significantly with the introduction of vesicular monoamine transporter 2 (VMAT2) inhibitors. These medications, such as valbenazine and deutetrabenazine, have been shown to be effective in reducing the severity of dyskinesia. They work by modulating the release of dopamine in the brain. The availability of these targeted therapies has been a major advance, offering patients a better chance of managing this challenging side effect. The future of treatment lies in the development of even more effective and tolerable therapies, as well as in strategies to prevent the development of Neuroleptic-induced dyskinesia in the first place.